parthenolide and Disease Exacerbation

parthenolide has been researched along with Disease Exacerbation in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cordes, N; Klebe, S; Morel, KL; Ormsby, RJ; Solly, EL; Sweeney, CJ; Sykes, PJ; Tran, LNK	1
Blanco, J; Egido, J; Gómez-Guerrero, C; Hernández-Vargas, P; Kopp, J; López-Franco, O; Sanjuán, G; Suzuki, Y; Yo, Y	1

Other Studies

2 other study(ies) available for parthenolide and Disease Exacerbation

Article	Year
Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. Clinical & experimental metastasis, 2018, Volume: 35, Issue:7 Topics: Adenocarcinoma; Animals; Disease Progression; Drug Interactions; Ethanol; Female; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Metastasis; Prostatic Neoplasms; Sesquiterpenes	2018
Nuclear factor-kappa B inhibitors as potential novel anti-inflammatory agents for the treatment of immune glomerulonephritis. The American journal of pathology, 2002, Volume: 161, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Division; Cells, Cultured; Chemokine CCL2; Disease Progression; Gene Expression Regulation; Gliotoxin; Glomerular Mesangium; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Humans; Inflammation; NF-kappa B; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Proteinuria; Rats; Sesquiterpenes	2002

Article

Year

Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide.

Clinical & experimental metastasis, 2018, Volume: 35, Issue:7

Topics: Adenocarcinoma; Animals; Disease Progression; Drug Interactions; Ethanol; Female; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Metastasis; Prostatic Neoplasms; Sesquiterpenes

2018

Nuclear factor-kappa B inhibitors as potential novel anti-inflammatory agents for the treatment of immune glomerulonephritis.

The American journal of pathology, 2002, Volume: 161, Issue:4

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Division; Cells, Cultured; Chemokine CCL2; Disease Progression; Gene Expression Regulation; Gliotoxin; Glomerular Mesangium; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Humans; Inflammation; NF-kappa B; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Proteinuria; Rats; Sesquiterpenes

2002